TIAN Xinping, LI Mengtao, ZENG Xiaofeng. Finding Possible Solutions for the Management of Systemic Lupus Erythematosus from the Current Situation and Challenges in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 169-173. DOI: 10.12290/xhyxzz.2022-0020
Citation: TIAN Xinping, LI Mengtao, ZENG Xiaofeng. Finding Possible Solutions for the Management of Systemic Lupus Erythematosus from the Current Situation and Challenges in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 169-173. DOI: 10.12290/xhyxzz.2022-0020

Finding Possible Solutions for the Management of Systemic Lupus Erythematosus from the Current Situation and Challenges in China

Funds: 

National Key Research and Development Program of China 2021YFC2501301-5

Beijing Municipal Science and Technology Commission Z201100005520022

Beijing Municipal Science and Technology Commission Z201100005520023

Beijing Municipal Science and Technology Commission Z201100005520025

Beijing Municipal Science and Technology Commission Z201100005520026

Beijing Municipal Science and Technology Commission Z201100005520027

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-005

More Information
  • Corresponding author:

    ZENG Xiaofeng, E-mail: xiaofeng.zeng@cstar.org.cn

  • Received Date: January 11, 2022
  • Accepted Date: January 17, 2022
  • Available Online: January 17, 2022
  • Issue Publish Date: March 29, 2022
  • Systemic lupus erythematosus(SLE) has become a common chronic autoimmune disease in China. It is estimated that there are about 1 million SLE patients in China. SLE in China has the characteristics of a large patient volume, high complication rate, heavy social and economic burden, and a great adverse impact on fertility. However, since rheumatology is the youngest subspecialty of internal medicine in China, and the distribution of rheumatologists is very uneven across the country, neither the quantity nor the quality of rheumatologists could meet the needs of SLE patients in China. This leads to the inadeguate standardization of the management, and the rates of remission and long-term survival of SLE patients in China lower than in the advanced nations. On the other hand, in China, SLE patients generally lack the knowledge of the disease, and the current system of managing chronic diseasesis far from perfect. All these have led to poor compliance with treatments and a low response rate. Therefore, the solutions for these difficulties and challenges might be setting up a nation-wide network for research and management of SLE, bringing the leadership of the National Clinical Research Center for Dermatological and immunological Diseases of China into full play, facilitating the development of rheumatology in China, building up a well-organized system for the management of chronic diseases, fully utilizing the policy for specialty development of government administrations, speeding up translational research and conducting high quality clinical studies.
  • [1]
    Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?[J]. J Rheumatol, 2005, 32: 1706-1708.
    [2]
    Zhu TY, Tam LS, Lee VW, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2009, 61: 1159-1167. DOI: 10.1002/art.24725
    [3]
    Zhang SQ, Han JW, Sun LD, et al. A single-nucleotide polymorphism of the TNFSF4 gene is associated with systemic lupus erythematosus in Chinese Han population[J]. Rheumatol Int, 2011, 31: 227-231. DOI: 10.1007/s00296-009-1247-2
    [4]
    Zhang Y, Yang J, Zhang J, et al. Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations[J]. Ann Rheum Dis, 2016, 75: 891-898.
    [5]
    Cheng YJ, Li MT, Zhao JL, et al. Chinese SLE Treatment and Research Group (CSTAR) registry: Ⅷ. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with SLE[J]. Int J Rheum Dis, 2018, 21: 716-724. DOI: 10.1111/1756-185X.13057
    [6]
    Li M, Zhang W, Leng X, et al. Chinese SLE Treatment and Research group (CSTAR) registry: Ⅰ. Major clinical characteristics of Chinese patients with systemic lupus erythematosus[J]. Lupus, 2013, 22: 1192-1199. DOI: 10.1177/0961203313499086
    [7]
    Zhang S, Su J, Li X, et al. Chinese SLE Treatment and Research group (CSTAR) registry: V. gender impact on Chinese patients with systemic lupus erythematosus[J]. Lupus, 2015, 24: 1267-1275. DOI: 10.1177/0961203315585813
    [8]
    Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese[J]. Lupus, 2011, 20: 767-771. DOI: 10.1177/0961203310388447
    [9]
    Guillotin V, Bouhet A, Barnetche T, et al. Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis[J]. Joint Bone Spine, 2018, 85: 663-668. DOI: 10.1016/j.jbspin.2018.03.006
    [10]
    Liu JT, Zhao Y, Song YJ, et al. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women[J]. J Matern Fetal Neonatal Med, 2012, 25: 261-266. DOI: 10.3109/14767058.2011.572310
    [11]
    霍春燕, 王丽. 系统性红斑狼疮患者服药相关知识和行为认知的调查[J]. 中华现代护理杂志, 2013, 19: 1023-1027.

    Huo CY, Wang L. Investigation of medication knowledge and behavior of systemic lupus erythematosus patients[J]. Zhonghua Xiandai Huli Zazhi, 2013, 19: 1023-1027.
    [12]
    王军霞, 沙悦, 陈嘉林. 北京市东城区全科医生对系统性红斑狼疮疾病认知的在线问卷调查[J]. 中华全科医学, 2019, 18: 832-836.

    Wang JX, ShaY, Chen JL. Online questionnaire survey on know-ledge of systemic lupus erythematosus among general practitioners in Beijing Dongcheng district[J]. Zhonghua Quanke Yixue, 2019, 18: 832-836.
  • Related Articles

    [1]BAO Xiaolin, WEI Hongjuan, BIAN Xinxin, MA Xiumei, GAO Yin, ZHANG Yingyan, LIU Wei, MA Yuexian, ZHANG Weixin, YANG Xuewen. Analysis and Prediction of Disease Burden of Depression in Old Age in China from 1990 to 2021[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 361-369. DOI: 10.12290/xhyxzz.2024-0664
    [2]ZHOU Yongtai, YANG Zhenyu, LI Yan, WU Jiajing, ZHAO Bo. Research Progress on the Mechanism of Lipocalin-2 in Neurological Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 330-337. DOI: 10.12290/xhyxzz.2025-0028
    [3]WU Haotian, LIN Jianhao. Disease Burden and Harm of Osteoarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 5-12. DOI: 10.12290/xhyxzz.2024-0969
    [4]WENG Xisheng, ZHANG Fengchun. Chronic Disease Management in Patients with Non-infectious Arthritis: Challenges and Solutions[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 1-4. DOI: 10.12290/xhyxzz.2024-0868
    [5]HUANG Danqi, YANG Min, XIONG Wei, LIU Jingyi, CHEN Wanqing, ZHAI Jingbo, LI Jiang. Analysis of Disease Burden and Attributable Risk Factors of Early-onset Female Breast Cancer in China and Globally from 1990 to 2021[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-1083
    [6]ZHAO Xiaoxiao, LU Xiaohui, KE Lixin, GAO Wulin, MENG Xiangran, REN Lili, DING Yunhan, ZHANG Qiang, XUN Yangqin, WU Jibiao, LU Cuncun. Investigation and Trend Prediction of Disease Burden of Hypertension in the Elderly Population Globally and in China from 1990 to 2021[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-1005
    [7]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [8]Shuang ZHOU, Yue LI. Castleman Disease Variant of POEMS Syndrome: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 202-206. DOI: 10.3969/j.issn.1674-9081.20170112
    [9]Chen-xi YU, Shui SUN. Roles of Long Noncoding RNAs in the Development and Progression of Osteoarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 85-90. DOI: 10.3969/j.issn.1674-9081.20170138
    [10]Yuan XIA, Xiang-pei LI. The Role of MicroRNA Regulation of Interferon-α in the Pathogenesis of Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 673-678. DOI: 10.3969/j.issn.1674-9081.2019.06.021
  • Cited by

    Periodical cited type(1)

    1. 周炯,刘爱民. 对接国际标准的高质量疾病分类:现状与思考. 协和医学杂志. 2024(05): 993-998 . 本站查看

    Other cited types(0)

Catalog

    Article Metrics

    Article views (1891) PDF downloads (386) Cited by(1)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close